Physician profile
Jesse Ballard
NPI 1629675699
$2,275.28
in general payments reported to CMS, 2019-2025
31 companies · $14.03 in 2025
The $14.03 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,663 · 2022: $144 · 2023: $233 · 2024: $222 · 2025: $14.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $373.40 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $357.84 | 2021-2024 | |
| Novo Nordisk INC | $251.98 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.06 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $127.72 | 2021 | |
| Xeris Pharmaceuticals, INC. | $123.80 | 2021 | |
| Lilly USA, LLC | $111.37 | 2021-2023 | Mounjaro, Trulicity |
| Medtronic, INC. | $59.10 | 2021 | |
| Merck Sharp & Dohme LLC | $56.49 | 2021-2022 | |
| Vivus LLC | $53.79 | 2021 | |
| Tandem Diabetes Care, INC. | $53.18 | 2021 | |
| Dexcom, INC. | $51.89 | 2021 | |
| Clarus Therapeutics INC. | $42.70 | 2021 | |
| Antares Pharma, INC. | $40.13 | 2021 | |
| Zealand Pharma US, INC. | $39.03 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $34.35 | 2024 | Auvelity |
| Amarin Pharma, INC. | $33.87 | 2021 | |
| Pfizer INC. | $33.66 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $24.27 | 2021 | |
| Amgen INC. | $23.97 | 2021 | |
| Daiichi Sankyo INC. | $23.36 | 2021 | |
| Amneal Pharmaceuticals LLC | $22.56 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.44 | 2023 | Quviviq |
| Organon LLC | $18.15 | 2023 | Nexplanon |
| Corcept Therapeutics | $17.19 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.78 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.75 | 2022 | |
| Inspire Medical Systems, INC. | $14.14 | 2023 | Inspire |
| Boston Scientific Corporation | $14.03 | 2025 | Wavewriter Alpha Prime 16 |
| Exact Sciences Corporation | $13.36 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.